Search Results
Results found for "Signe Mathiasen"
Posts (38)
- Sign Up Now!
Sign up now ➡️ https://bit.ly/3eaO5PH #gpcr #drgpcr
- Sign Up Now!
Sign up now! ➡️ https://www.ecosystem.drgpcr.com/explore-individuals #gpcr #drgpcr
- Cancer Research UK and Sosei Heptares sign agreement to advance cancer immunotherapy candidate ...
July 2022 Cancer Research UK and Sosei Heptares sign agreement to advance cancer immunotherapy candidate , and Cancer Research UK, the world’s largest private funder of cancer research, today announce the signing
Other Pages (21)
- Session I | Adhesion GPCR Workshop 2024 | Dr. GPCR Ecosystem
Mathiasen An ECR-Mediated and TA-independent Mechanism of aGPCR Activation: Direct Communication of Mathiasen Abstract Only available for AGPCR 24 Workshop Attendees Authors & Affiliations "Rosell, Júlia , Signe (1) 1. Mathiasen "2022-present Assistant Professor (Tenure Track) and Group Leader Department of Biomedical Signe Mathiasen on the web University of Copenhagen Mathiasen Group An ECR-Mediated and TA-independent
- Full Agenda for Adhesion GPCR Workshop 2024 | Dr. GPCR Ecosystem
Read More 3:00 PM Session I Tethered agonist - dependent/independent activation mechanism in AGPCRs Signe Mathiasen · Demet Araç · Andrew Dates · Frank Kwarcinski · Peng Xiao Read More 4:30 PM Leaving for City memory function in mice potentially through neuronal and neuroimmune alterations during neurodevelopment Signe Mathiasen Signaling Properties of ADGRL3 Monserrat Avila Zozaya The ADGRF5/GPR116 receptor is a key
- 🎯 Crack the code of GPCR ligand development! In case you haven’t heard, Dr. Terry Kenakin is hosting a 4-week course on GPCR drug development—and registration closes in 3 days! ⚠️ What you’ll learn: ✅ Drug absorption, metabolism & clearance ✅ PK-PD modeling & therapeutic profiles ✅ Early safety assessments & toxicity risks 📌 Limited spots—sign up before March 18th! 👉 Development of GPCR Ligands as Therapeutic Drugs | Dr. GPCR Ecosystem #GPCR #DrGPCR #Pharma #Biotech #Research | Dr. GPCR Ecosystem
PK-PD modeling & therapeutic profiles ✅ Early safety assessments & toxicity risks 📌 Limited spots—sign ✅ PK-PD modeling & therapeutic profiles✅ Early safety assessments & toxicity risks 📌 Limited spots—sign
